Vertex: The Quiet Biotech Compounder I'd Happily Hold Through Any Market Crash

Vertex has the revenue power to excel during any market environment.Vertex Pharmaceuticals (VRTX 2.88%) hasn't made the headlines in recent times like companies involved in high-growth areas such as weight loss drugs or artificial intelligence (AI). But this biotech player has proven its ability over time to develop successful drugs, generate earnings growth, and continue to innovate. Vertex is the global leader in cystic fibrosis (CF) treatment and over the past couple of years branched out into other areas by winning approval for a gene editing treatment for blood disorders and a drug for pain management. All of this should sustain earnings growth during any economic backdrop -- and that's why I would hold this quiet biotech compounder through any market crash. Image source: Getty Images. Growing your initial investment First, what do I mean by "compounder"? By this, I mean that Vertex stock has what it takes to gain, increasing the value of your initial investment. And as that value then climbs over time, you'll benefit from greater returns. So, investing in Vertex, holding on, and even adding to your investment could be a winning strategy over time -- of course, this is as part of a diversified portfolio of other stocks as well. It's never a good idea to invest in only one or two stocks, no matter how wonderful the company or companies may be. Now, let's consider why you should have confidence in Vertex. As I mentioned, the company is the leader worldwide in the treatment of CF. Its drugs have been game changers for CF patients and their families, meaningfully extending lives and improving quality of life. Vertex makes CFTR modulators, therapies that fix the faulty protein made by the CFTR gene. There are many genetic mutations involved in CF, but Vertex's drugs have the ability to handle about 90% of them -- so much of the CF community may be served by these drugs. And Vertex is working on a candidate that would address those who aren't candidates for CFTR modulators. Vertex's intellectual property strength Vertex's solid intellectual property supports leadership in CF well through the coming decade, so this is a portfolio investors can count on for stability and growth. On top of this, Vertex is seeing positive progress in the rollout of its gene editing treatment Casgevy and pain drug Journavx. The company recently said it expects these non-CF products to add $500 million or more to revenue this year. And the company announced total revenue guidance for the year of as much as $13.1 billion. All of Vertex's treatments are ones patients need and won't drop during a potentially difficult economy. That's why I would hold this quiet compounder at any time -- including through any market crash.Read NextFeb 13, 2026 •By James BrumleyWhy CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss)Feb 10, 2026 •By Adria Cimino1 Reason I'd Buy Vertex Pharmaceuticals Stock and Never SellFeb 10, 2026 •By James HalleyShould You Buy Vertex Before Feb. 12?Feb 9, 2026 •By Prosper Junior BakinyShould You Buy Vertex Pharmaceuticals Before Feb. 12?Jan 29, 2026 •By Prosper Junior BakinyPrediction: 2026 Will Be the Year of Vertex PharmaceuticalsJan 9, 2026 •By Prosper Junior BakinyPrediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026About the AuthorAdria Cimino is a contributing Motley Fool stock market analyst covering healthcare, technology, and consumer goods sectors. Prior to The Motley Fool, Adria covered the European stock market and U.S. stocks pre-market trading for Bloomberg News, Bloomberg TV, and Bloomberg Radio for more than a decade. Earlier in her career, she wrote about biotech, medtech, and technology companies in Boston for Mass High Tech, an American City Business Journals publication. She holds a bachelor’s degree in mass communications from the University of South Florida.TMFAdriaCiminoX@adria_in_parisStocks MentionedVertex PharmaceuticalsNASDAQ: VRTX$477.32 (2.88%) $14.15*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.